Lotte Bjerre Knudsen is a Scientific Corporate Vice President in the research organisation of the pharmaceutical company Novo Nordisk in Denmark. Originally trained in biotechnology, she also has a Doctor of Medical Sciences and is an Adjunct Professor in translational medicine at Aarhus University, Denmark. She has worked for Novo Nordisk for 30 years and has had a leading role in progressing Glucagon-Like Peptide-1 (GLP-1) based drug design and mechanistic understanding. Her publications cover a broad scope with regards to GLP-1’s effects in diabetes, cardiovascular disease and obesity, with a focus in recent years on understanding more about the neural role of GLP-1. Apart from its role as a metabolic hormone, GLP-1 is a neurotransmitter/neuromodulator, and the GLP-1 receptor has widespread brain expression. Given that GLP-1 lowers systemic inflammation, some of Dr Knudsen’s ongoing research is investigating whether GLP-1may also be a regulator of central inflammation via effects on microglia and astrocytes.